Lineage Cell Therapeutics Joins 2024 Russell 3000 Index

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company specializing in allogeneic cell therapies for unmet medical needs, has been inducted as a member of the Russell 3000® Index. This inclusion will be effective after the U.S. market opens on July 1, 2024, coinciding with the annual reconstitution of the Russell indexes, which identifies the 4,000 largest U.S. stocks based on total market capitalization as of April 30, 2024. Membership in the Russell 3000® Index secures a place in either the large-cap Russell 1000® Index or the small-cap Russell 2000® Index, along with the relevant growth and value style indexes. FTSE Russell, known for its objective, market-capitalization rankings and style attributes, oversees the membership criteria for these indexes.

Brian M. Culley, CEO of Lineage, expressed satisfaction with the continued inclusion in the Russell 3000, highlighting its potential to enhance investor awareness, institutional ownership, and stock liquidity. He emphasized that this recognition comes at a pivotal moment for the company, which aims to garner more support for its innovative cell transplant medicine strategies.

Russell indexes serve as key tools for investment managers and institutional investors, who use them for index funds and as benchmarks for active investment strategies. Data from December 2023 indicates that approximately $10.5 trillion in assets are benchmarked against the Russell US indexes, managed by FTSE Russell, a prestigious global index provider. Fiona Bassett, CEO of FTSE Russell, noted that the Russell indexes, now in their 40th year, continue to adapt to reflect the dynamic U.S. economy, with annual rebalancing playing an essential role in maintaining accurate, unbiased benchmarks.

Lineage Cell Therapeutics focuses on developing "off-the-shelf" cell therapies to meet unaddressed medical needs. Their proprietary cell-based technology platform facilitates the development and manufacturing of specialized human cells designed to emulate naturally occurring cells in the human body. These cells are created through directed differentiation protocols applied to self-renewing pluripotent cell lines, generating cells with characteristics tailored to specific developmental lineages. The objective is to transplant these cells into patients to replace or support dysfunctional or absent cells due to degenerative diseases, aging, or injuries, thereby restoring or enhancing functional activity.

Lineage’s current neuroscience pipeline includes several key programs:

1. OpRegen®: A retinal pigment epithelial cell therapy in Phase 2a development, in collaboration with Roche and Genentech, targeting geographic atrophy secondary to age-related macular degeneration.
2. OPC1: An oligodendrocyte progenitor cell therapy in Phase 1/2a development for spinal cord injuries.
3. ANP1: An auditory neuronal progenitor cell therapy aimed at treating auditory neuropathy.
4. PNC1: A photoreceptor neural cell therapy for addressing vision loss due to photoreceptor dysfunction or damage.
5. RND1: A hypoimmune induced pluripotent stem cell line developed in partnership with Eterna Therapeutics Inc.

By leveraging its advanced platform, Lineage aims to deliver groundbreaking treatments for conditions with significant unmet medical needs, thereby advancing the field of cell transplant medicine.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!